Investment
Features
FeesSafety
Academy
More
Pluang+

Ondo's Oasis Pro Markets joins DTCC Fund/SERV as first tokenization-platform member for US mutual funds

Protocol Fundamentals
18 Sep 2026
Crypto Daily
View Source
Bullish
Ondo's Oasis Pro Markets joins DTCC Fund/SERV as first tokenization-platform member for US mutual funds

Ondo Finance's broker-dealer subsidiary, Oasis Pro Markets, has become the first tokenization-platform member of DTCC Fund/SERV, a major US mutual-fund processing network handling over 85% of transactions. This membership integrates Ondo's tokenized funds into established fund distribution and back-office systems, enabling streamlined account-data exchange, transaction confirmations, reconciliations, and regulatory reporting. The move enhances Ondo's operational access to existing fund-market workflows without needing bespoke setups for each partner, supporting broader adoption of tokenized fund products under regulatory oversight. This development follows Oasis Pro's recent FINRA authorizations for tokenized securities in the US market.

Ondo Finance's recent DTCC Fund/SERV membership is noted here with Pluang market data as of Sep 18, 2026 17:54 WIB: Among 50 major cryptocurrencies priced on Pluang, 46 rose and 3 fell today. Notable gainers include THETA at Rp3.714 with a 16.57% increase and 100% buy order activity, COTI at Rp382 up 13.64%, and SUSHI at Rp4.420 rising 12.84%.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
24 minutes ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
1 hour ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App